Wearable Monitoring for Early Cardiotoxicity Detection in Cancer Patients: The COMPASS Vision
V Barbuto, C Savaglio, IS Curren, G Liuzzo, L Natale, S Gravina, SJ Archibald, R Gravina
Abstract
Cancer therapies have substantially improved survival outcomes, yet cancer therapy-related cardiovascular toxicity (CTR-CVT) remains a major concern, with approximately one in four anticancer drugs carrying cardiac or vascular safety warnings. Since current monitoring relies on periodic hospital-based assessments, transient or progressively evolving cardiovascular alterations often escape timely detection. Within the context of COMPASS (Cardio-Oncology Multidisciplinary Patient Assistance Solution), an EU Innovative Health Initiative (IHI) project (Grant Agreement No. 101253264), this extended abstract explores continuous wearable sensing in real-world environments as a complementary paradigm for early detection of CTR-CVT. After reviewing the clinical indicators most relevant to longitudinal monitoring, we survey the corresponding wearable modalities together with their typical accuracy ranges and metrological limitations, and introduce the COMPASS research vision integrating wearable-derived data into AI-based clinical decision support for personalized cardio-oncology care.